Tesamorelin typically takes 13 to 26 weeks to produce measurable results. The first biological changes begin within weeks as growth hormone levels rise, but visible reductions in belly fat generally require three to six months of daily injections. How quickly you notice changes depends on what you’re measuring: hormone levels shift earlier, while fat loss takes longer to become apparent.
How Tesamorelin Works in Your Body
Tesamorelin is a synthetic version of a hormone your brain naturally produces to tell the pituitary gland to release growth hormone. When you inject it daily, it triggers your pituitary to ramp up its own growth hormone output. That extra growth hormone then drives a chain of effects, including increased fat breakdown, particularly in the deep abdominal fat surrounding your organs (visceral fat).
One key marker doctors track is IGF-1, a protein your liver produces in response to growth hormone. Rising IGF-1 levels are the earliest measurable sign that tesamorelin is doing its job. In clinical trials, significant IGF-1 elevations appeared as early as 13 weeks, with 47% of patients showing notably high levels by week 26.
The Fat Loss Timeline
Visceral fat reduction is the primary reason tesamorelin is prescribed, and the data from Phase 3 trials gives a fairly clear picture of what to expect. At 26 weeks (about six months), patients lost an average of 15.4% of their visceral fat compared to placebo. That translated to roughly 24 square centimeters of visceral fat area disappearing on CT scans.
For patients who continued treatment through a full year, the results improved modestly. At 52 weeks, the average reduction reached about 17.5%. The improvement between six months and twelve months is real but smaller than the initial drop, suggesting most of the benefit comes in the first half-year.
Not everyone responds equally. In clinical trials, researchers defined a “responder” as someone who lost at least 8% of their visceral fat. By that standard, 69% of tesamorelin patients qualified as responders at 26 weeks, and 72% at 52 weeks. That means roughly 3 in 10 people don’t hit that threshold even after months of treatment.
What the First Few Months Feel Like
The honest answer is that you probably won’t notice dramatic changes in the mirror during the first month or two. Visceral fat sits deep inside the abdomen, wrapped around organs, so even meaningful reductions on a CT scan may not translate to obvious visual changes right away. The early weeks are a period where your growth hormone levels are climbing but fat loss hasn’t accumulated enough to feel different.
By month three, some people begin noticing their waistline feels slightly different or clothes fit a bit looser around the midsection. But the clinical data suggests the more reliable, measurable changes cluster around the four-to-six-month mark. If you’re expecting rapid results in the first few weeks, this medication works on a slower timeline than that.
Blood Sugar Changes to Be Aware Of
Because growth hormone affects how your body handles sugar, tesamorelin can nudge blood glucose levels upward. In Phase 3 trials, 4.5% of patients on tesamorelin developed elevated HbA1c (a three-month average of blood sugar) compared to 1.3% on placebo. The overall difference in average HbA1c between the two groups was small, about 0.12%, but the relative risk of crossing into a diabetic range was roughly three times higher on tesamorelin.
Interestingly, fasting blood sugar and fasting insulin levels didn’t differ significantly between tesamorelin and placebo at 26 weeks. And for patients who continued through a full year, those glucose markers stayed stable. So the blood sugar effect appears modest for most people, but it’s something worth monitoring, especially if you already have prediabetes or diabetes risk factors.
What Happens If You Stop
Tesamorelin’s effects don’t persist after discontinuation. In clinical trials, patients who were switched from tesamorelin to placebo at the 26-week mark saw their visceral fat begin returning. The medication works by keeping growth hormone output elevated, and once you stop injecting, your pituitary reverts to its baseline output. The fat reduction you achieved gradually reverses.
This is an important consideration when thinking about timelines. Tesamorelin isn’t a short course that produces lasting changes. It requires ongoing daily use to maintain its effects, which means the “how long does it take to work” question is really about how long until you reach a new steady state that you then maintain with continued treatment.
Current Dosing
Tesamorelin is available in two formulations with different dosing. The newer multi-dose vial (EGRIFTA WR) delivers 1.28 mg per day as a subcutaneous injection, with one reconstituted vial lasting seven consecutive days. The older single-dose formulation (EGRIFTA SV) uses a different dose and preparation. The two are not interchangeable, so the specific version you’re prescribed determines your exact daily routine.
Regardless of formulation, the clinical trial timelines described above were based on consistent daily injections. Missing doses or using the medication inconsistently would likely delay results, though there isn’t specific data quantifying how much irregular use slows the timeline.
Setting Realistic Expectations
The most useful way to think about tesamorelin’s timeline is in phases. During weeks 1 through 6, your growth hormone and IGF-1 levels are rising, but you’re unlikely to see or feel fat loss yet. From weeks 6 through 13, your body is actively breaking down visceral fat, and some people begin noticing subtle changes. By weeks 13 through 26, the majority of the fat reduction effect has occurred, and this is when measurable differences show up clearly on imaging. Beyond 26 weeks, continued use produces additional but more incremental improvement.
If you’ve been using tesamorelin consistently for six months and haven’t seen meaningful results, you may fall into the roughly 30% of patients who don’t respond strongly to the medication. That’s a reasonable point to reassess with your prescriber whether continuing makes sense.